Of note, BCR can represent local recurrence and increases the risk of metastasis and PCa-specific mortality (PCSM) in patients with prognostically unfavorable pre- and post-treatment clinicopathological factors, including a high Gleason score (GS) and a short PSA doubling time (PSADT) [5–7]. This evidence concerns the gene BCR and posterior cortical atrophy.